(+)-(S)-4,5,6,7-tetrahydro-5-methylimidazo<4,5,1-jk><1,4>benzodiazepin-2(1H)-one | 126233-80-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: (+)-(S)-4,5,6,7-tetrahydro-5-methylimidazo<4,5,1-jk><1,4>benzodiazepin-2(1H)-one
• 英文别名: S-(+)-4,5,6,7-Tetrahydro-5-methylimidazo(4,5,1-jk)(1,4)benzodiazepin-2(1H)-one；(11S)-11-methyl-1,3,10-triazatricyclo[6.4.1.04,13]trideca-4,6,8(13)-trien-2-one
• CAS: 126233-80-5
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: GTNCOIIPIKEYMW-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+)-(S)-4,5,6,7-tetrahydro-5-methylimidazo<4,5,1-jk><1,4>benzodiazepin-2(1H)-one 在 4-二甲氨基吡啶 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 46.0h， 生成 (+)-(S)-1,2,4,5,6,7-hexahydro-5-methyl-2-oxoimidazo<4,5,1-jk><1,4>benzodiazepine-8-carbonitrile
  参考文献：
  名称：

  Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TlBO) Derivatives. 4

  摘要：

  In previous papers, we have described the discovery of a new series of compounds, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones, TlBO (1 and 1a), with potent anti-HIV-1 activity and the synthesis of analogues to better define the structure-activity relationships (SAR) in terms of changes in substituents at the N-6 position and variations of the five-membered urea ring as well as the seven-membered diazepine ring. This paper describes the synthesis of TlBO analogues with various substituents on the aromatic ring and their SAR in terms of anti-HIV-1 properties. Substituents on the 8-position furnished the most rewarding results and gave a large improvement in potency versus the parent compound. These included halogen, thiomethyl, and methyl. Analogues like 8-cyano, -methoxy, and -acetylene were equipotent, while 8-amino, -acetylamino, -dimethylamino, and -nitro were inactive (Table 1). Substituents at the 9-position tended to have little effect on activity, and 10-substituents decreaseed activity. The 8-chloro compound 6a with IC50 = 0.0043 mu M is currently under clinical development.

  DOI：

  10.1021/jm00005a006
• 作为产物：
  描述：

  2-氨基-3-硝基苯甲酸 在 palladium on activated charcoal N-甲基吗啉 、 lithium aluminium tetrahydride 、 氢气 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， -12.0~200.0 ℃ 、310.27 kPa 条件下， 反应 72.42h， 生成 (+)-(S)-4,5,6,7-tetrahydro-5-methylimidazo<4,5,1-jk><1,4>benzodiazepin-2(1H)-one
  参考文献：
  名称：

  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives

  摘要：

  A series of 6-substituted 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (9) have been synthesized and tested for their ability to inhibit the replication of the HIV-1 virus in MT-4 cells. Two synthetic methods are described, one of which allows the synthesis of single enantiomers of the final products. A structure-activity study was done within the series of compounds to determine the optimum group for the 6-position substitution and to determine whether the activity was enantiospecific at the 5-position, which was substituted with a methyl group. The best analogue, 9jj, inhibited HIV-1 with an IC50 of 4-mu-M, which is comparable to the activity level of DDI, a 2',3'-dideoxynucleoside-type structure undergoing clinical trials as an anti-AIDS therapy.

  DOI：

  10.1021/jm00106a040

文献信息

• Imidazol-4-ylpiperidine derivatives, their preparation and their
  申请人：Synthelabo

  公开号：US05589476A1

  公开（公告）日：1996-12-31

  A compound of formula (I): ##STR1## in which R.sub.1 represents a hydrogen atom or a straight or branched (C.sub.1 -C.sub.4)alkyl group; and A represents a 5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, a 4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 4-phenylmethyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yl group, a 5,6-dihydro-4H-imidazo[1,5,4-de]quinoxalin-2-yl group, a 6-oxo-5,6-dihydro-4H-imidazo[4,5,1-ij]quinol-2-yl group, or a 5-methyl-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2-yl group which may be unsubstituted or substituted in the 6-position by a phenylmethyl group; or an addition salt thereof with a pharmaceutically acceptable acid.

  式（I）的化合物：##STR1##其中R.sub.1代表氢原子或直链或支链（C.sub.1-C.sub.4）烷基基团；A代表5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2-基基团，4,5-二氢咪唑并[1,5,4-de][1,4]苯并噁唑-2-基基团，4-甲基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并噁唑-2-基基团，4-苯基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并噁唑-2-基基团，4-苯甲基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并噁唑-2-基基团，5-甲基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并噁唑-2-基基团，5,6-二氢-4H-咪唑并[1,5,4-de]喹啉-2-基基团，6-氧代-5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2-基基团，或5-甲基-4,5,6,7-四氢咪唑并[4,5,1-jk][1,4]苯并二氮杂环-2-基基团，该基团可以在6位被苯甲基基团取代或未取代；或其与药学上可接受的酸形成的盐。
• Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 2
  作者：Michael J. Kukla、Henry J. Breslin、Craig J. Diamond、Philip P. Grous、Chih Y. Ho、Milton Miranda、James D. Rodgers、Ronald G. Sherrill、Erik De Clercq、Rudi Pauwels、Koen Andries、Luc J. Moens、Marcel A. C. Janssen、Paul A. J. Janssen

  DOI：10.1021/jm00115a007

  日期：1991.11.1

  substituent (R) attached at the N-6 position of 9. This study describes the syntheses and anti-HIV-1 testing of analogues with variations of the five-membered urea ring of the 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) structures. Although many different rings were synthesized to replace the cyclic urea of TIBO, most were found to be inactive in inhibiting the replication

  在该系列的第一篇论文中，揭示了一种具有抗HIV-1活性的新结构，并合成了类似物以探讨9位N-6位上连接的取代基（R）的变化与构效关系。描述了具有4,5,6,7-四氢-5-甲基咪唑[4,5,1-jk] [1,4]的五元脲环变异的类似物的合成和抗HIV-1测试苯并二氮杂-2-2（1H）-一（TIBO）结构。尽管合成了许多不同的环来取代TIBO的环状脲，但发现大多数环在抑制MT-1细胞中HIV-1病毒的复制方面没有活性。例外是用硫或硒代替尿素氧，得到相应的硫脲或硒脲。发现它们比氧气对应物更具活性。合成并测试了一小部分类似物，可以直接比较尿素和硫脲衍生物。毫无例外，后者总是比前者更加活跃。发现该系列（8d）中活性最高的化合物抑制HIV-1病毒，其IC50为0.012 microM，与AZT相当。
• Dérivés d'imidazol-4-yl-pipéridine, leur préparation et leur application en thérapeutique
  申请人：SYNTHELABO

  公开号：EP0646583A1

  公开（公告）日：1995-04-05

  Composés répondant à la formule (I) dans laquelle R₁ représente soit un atome d'hydrogène, soit un groupe (C₁-C₆)alkyle droit ou ramifié et A représente soit un groupe 5,6-dihydro-4H-imidazo[4,5,1-ij] quinoléin-2-yle, soit un groupe 4,5-dihydroimidazo[1,5,4-de] [1,4]benzoxazin-2-yle, soit un groupe 4-méthyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yle, soit un groupe 4-phényl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2-yle, soit un groupe 4-(phénylméthyl)-4,5-dihydroimidazo[1,5,4-de][1,4] benzoxazin-2-yle, soit un groupe 5-méthyl-4,5-dihydroimidazo[1,5,4-de] [1,4]benzoxazin-2-yle, soit un groupe 5,6-dihydro-4H-imidazo[1,5,4-de]quinazolin-2-yle, soit un groupe 6-oxo-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoléin-2-yle, soit un groupe 5-méthyl-4,5,6,7-tétrahydroimidazo[4,5,1-jk][1,4] benzodiazépin-2-yle éventuellement substitué en 6 par un groupe phénylméthyle ainsi que leurs sels d'additions aux acides pharmaceutiquement acceptables. Les composés de l'invention sont des ligands des récepteurs sérotoninergiques de types 5-HT₃ et 5-HT₄.

  与式（I）对应的化合物 其中 R₁ 代表氢原子或直链或支链（C₁-C₆）烷基，以及 A 代表 5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2-基团，或 4,5-二氢咪唑并[1,5,4-de][1,4]苯并恶嗪-2-基团，或 4-甲基-4,5-二氢咪唑并[1,5,4-de][1、4]苯并恶嗪-2-基，或 4-苯基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并恶嗪-2-基，或 4-(苯基甲基)-4,5-二氢咪唑并[1,5,4-de][1,4]苯并恶嗪-2-基，或 5-甲基-4、5-甲基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并恶嗪-2-基，或 5-甲基-4,5-二氢咪唑并[1,5,4-de]喹唑啉-2-基，或 6-氧代-5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2-基，或 5-甲基-4,5-二氢咪唑并[1,5,4-de][1,4]苯并恶嗪-2-基、5,6,7-四氢咪唑并[4,5,1-jk][1,4]苯并二氮杂卓-2-基团，可选择在第 6 位被苯基甲基取代，以及它们与药学上可接受的酸的加成盐。本发明的化合物是 5-HT₃ 和 5-HT₄ 型血清素受体的配体。
• Pfaendler, Hans Rudolf; Weisner, Frank, Heterocycles, 1995, vol. 40, # 2, p. 717 - 728
  作者：Pfaendler, Hans Rudolf、Weisner, Frank

  DOI：——

  日期：——
• KUKLA, MICHAEL J.;BRESLIN, HENRY J.;PAUWELS, RUDI;FEDDE, CYNTHIA L.;MIRAN+, J. MED. CHEM., 34,(1991) N, C. 746-751
  作者：KUKLA, MICHAEL J.、BRESLIN, HENRY J.、PAUWELS, RUDI、FEDDE, CYNTHIA L.、MIRAN+

  DOI：——

  日期：——